Gwenn S Smith, Xiaohua Li and P Jeffrey Conn

Neuropsychopharmacology 37: 1-3; doi:10.1038/npp.2011.233



From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment

Bita Moghaddam and Daniel Javitt

Neuropsychopharmacology 37: 4-15; advance online publication, September 28, 2011; doi:10.1038/npp.2011.181

Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia

Carrie K Jones, Nellie Byun and Michael Bubser

Neuropsychopharmacology 37: 16-42; advance online publication, September 28, 2011; doi:10.1038/npp.2011.199

Cognitive Training for Impaired Neural Systems in Neuropsychiatric Illness

Sophia Vinogradov, Melissa Fisher and Etienne de Villers-Sidani

Neuropsychopharmacology 37: 43-76; advance online publication, November 2, 2011; doi:10.1038/npp.2011.251

Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development

Xiaohua Li, Mark A Frye and Richard C Shelton

Neuropsychopharmacology 37: 77-101; advance online publication, September 7, 2011; doi:10.1038/npp.2011.198

Somatic Treatments for Mood Disorders

Moacyr A Rosa and Sarah H Lisanby

Neuropsychopharmacology 37: 102-116; advance online publication, October 5, 2011; doi:10.1038/npp.2011.225

Cognitive Mechanisms of Treatment in Depression

Jonathan P Roiser, Rebecca Elliott and Barbara J Sahakian

Neuropsychopharmacology 37: 117-136; advance online publication, October 5, 2011; doi:10.1038/npp.2011.183

Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior

Ebrahim Haroon, Charles L Raison and Andrew H Miller

Neuropsychopharmacology 37: 137-162; advance online publication, September 14, 2011; doi:10.1038/npp.2011.205

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Giovanni Addolorato, Lorenzo Leggio, F Woodward Hopf, Marco Diana and Antonello Bonci

Neuropsychopharmacology 37: 163-177; advance online publication, October 26, 2011; doi:10.1038/npp.2011.216

Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond

Christina Gross, Elizabeth M Berry-Kravis and Gary J Bassell

Neuropsychopharmacology 37: 178-195; advance online publication, July 27, 2011; doi:10.1038/npp.2011.137

Networking in Autism: Leveraging Genetic, Biomarker and Model System Findings in the Search for New Treatments

Jeremy Veenstra-VanderWeele and Randy D Blakely

Neuropsychopharmacology 37: 196-212; advance online publication, September 21, 2011; doi:10.1038/npp.2011.185

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

Yoland Smith, Thomas Wichmann, Stewart A Factor and Mahlon R DeLong

Neuropsychopharmacology 37: 213-246; advance online publication, September 28, 2011; doi:10.1038/npp.2011.212

Epigenetic Treatments for Cognitive Impairments

Jeremy J Day and J David Sweatt

Neuropsychopharmacology 37: 247-260; advance online publication, May 18, 2011; doi:10.1038/npp.2011.85

Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development

Alena V Savonenko, Tatiana Melnikova, Andrew Hiatt, Tong Li, Paul F Worley, Juan C Troncoso, Phil C Wong and Don L Price

Neuropsychopharmacology 37: 261-277; advance online publication, September 21, 2011; doi:10.1038/npp.2011.211



New Era for Novel CNS Drug Development

William Z Potter

Neuropsychopharmacology 37: 278-280; doi:10.1038/npp.2011.186

Translating Discoveries into Medicine: Psychiatric Drug Development in 2011

Linda S Brady and Thomas R Insel

Neuropsychopharmacology 37: 281-283; doi:10.1038/npp.2011.106

NIA Commentary: Translational Issues in Alzheimer's Disease Drug Development

Neil S Buckholtz, Laurie M Ryan, Suzana Petanceska and Lorenzo M Refolo

Neuropsychopharmacology 37: 284-286; doi:10.1038/npp.2011.116

Neuroscience Networking: Linking Discovery to Drugs

Jill Heemskerk, Rebecca Farkas and Petra Kaufmann

Neuropsychopharmacology 37: 287-289; doi:10.1038/npp.2011.177

New Medications for Substance Use Disorders: Challenges and Opportunities

Nora D Volkow and Phil Skolnick

Neuropsychopharmacology 37: 290-292; doi:10.1038/npp.2011.84

The Role of Complementary, Alternative, and Integrative Medicine in Personalized Health Care

Emmeline Edwards

Neuropsychopharmacology 37: 293-295; doi:10.1038/npp.2011.92


Hot Topics

Grateful DREADDs: Engineered Receptors Reveal How Neural Circuits Regulate Behavior

Susan M Ferguson and John F Neumaier

Neuropsychopharmacology 37: 296-297; doi:10.1038/npp.2011.179

Dopamine D3 Receptor Function and Cocaine Exposure

Brandi L Blaylock and Michael A Nader

Neuropsychopharmacology 37: 297-298; doi:10.1038/npp.2011.170

Chronic N-acetylcysteine after cocaine self-administration produces enduring reductions in drug-seeking

Carmela M Reichel and Ronald E See

Neuropsychopharmacology 37: 298; doi:10.1038/npp.2011.164

Methamphetamine-Induced Oxidation of Proteins and Alterations in Protein Processing

Bryan K Yamamoto and Fu-Chen Yang

Neuropsychopharmacology 37: 298-299; doi:10.1038/npp.2011.173

Placental Source for 5-HT that Tunes Fetal Brain Development

Alexandre Bonnin and Pat Levitt

Neuropsychopharmacology 37: 299-300; doi:10.1038/npp.2011.194

Mainstreaming Mice

Brooke A Babineau, Mu Yang and Jacqueline N Crawley

Neuropsychopharmacology 37: 300-301; doi:10.1038/npp.2011.168

Phospholipase D as a Therapeutic Target in Brain Disorders

Craig W Lindsley and H Alex Brown

Neuropsychopharmacology 37: 301-302; doi:10.1038/npp.2011.178

Transferrin Antibodies Into the Brain

Mark S Dennis and Ryan J Watts

Neuropsychopharmacology 37: 302-303; doi:10.1038/npp.2011.196

Endogenous Opioids as Physiological Antidepressants: Complementary Role of Delta Receptors and Dopamine

Emily M Jutkiewicz and Bernard P Roques

Neuropsychopharmacology 37: 303-304; doi:10.1038/npp.2011.244

Oxytocin as a Potential Therapeutic Target for Schizophrenia and Other Neuropsychiatric Conditions

David Feifel

Neuropsychopharmacology 37: 304-305; doi:10.1038/npp.2011.184

Dysregulation of mTOR Signaling in Neuropsychiatric Disorders: Therapeutic Implications

Kirsty Sawicka and R Suzanne Zukin

Neuropsychopharmacology 37: 305-306; doi:10.1038/npp.2011.210

Habenular Signaling in Nicotine Reinforcement

Christie D Fowler and Paul J Kenny

Neuropsychopharmacology 37: 306-307; doi:10.1038/npp.2011.197

Circuits, Cells, and Synapses: Toward a New Target for Deep Brain Stimulation in Depression

Fritz A Henn

Neuropsychopharmacology 37: 307-308; doi:10.1038/npp.2011.193

Update on Corticotropin-Releasing Factor Pharmacotherapy for Psychiatric Disorders: A Revisionist View

George F Koob and Eric P Zorrilla

Neuropsychopharmacology 37: 308-309; doi:10.1038/npp.2011.213

Update on Omega-3 Polyunsaturated Fatty Acids in Early-Stage Psychotic Disorders

G Paul Amminger and Patrick D McGorry

Neuropsychopharmacology 37: 309-310; doi:10.1038/npp.2011.187

Beyond Antipsychotics: Pharmacologically-Augmented Cognitive Therapies (PACTs) for Schizophrenia

Neal R Swerdlow

Neuropsychopharmacology 37: 310-311; doi:10.1038/npp.2011.195

From Father to Offspring: Paternal Transmission of Depressive-Like Behaviors

David M Dietz and Eric J Nestler

Neuropsychopharmacology 37: 311-312; doi:10.1038/npp.2011.167

Main navigation

ACNP resources

NPG resources

Extra navigation

21 November 2019